Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS449884 in Type 2 Diabetes Mellitus
CTR20190151Phase 2Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Jul 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ISIS 449884 in type 2 diabetes mellitus (T2DM), sponsored by Suzhou Ribo Life Science Co., Ltd.. Started Jul 2019; status: completed.
02
Drugs
ISIS 449884
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20190151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190151.